VIVO BIO TECH LTD.

Vivo Bio Tech Ltd has announced the closure of its trading window for all insiders, including designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will remain shut from July 01, 2026, until 48 hours after the declaration of the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. This measure is intended to prevent potential insider trading activities.

Vivo Bio Tech Ltd has announced a change in its Company Secretary and Compliance Officer. Mr. A V Kiran has ceased to hold the position effective June 24, 2026. The Board of Directors has authorized Mr. Bhavish Vijayvargiya to act as the Company Secretary & Compliance Officer. Mr. Vijayvargiya will be responsible for determining the materiality of events and advising on disclosures to the stock exchanges. His contact details have been provided for official communication.

Vivo Bio Tech Ltd announced a change in its key management personnel. Mr. A V Kiran has resigned as Company Secretary and Compliance Officer, effective June 24, 2026, to pursue other career opportunities. Concurrently, the Board of Directors, upon the recommendation of the Nomination and Remuneration Committee, has appointed Mr. Bhavish Vijayvargiya as the new Company Secretary and Compliance Officer, also effective June 24, 2026. Mr. Vijayvargiya is an Associate Member of the Institute of Company Secretaries of India with experience in corporate secretarial functions and compliance management.

Shri Shri Resorts Private Limited, a promoter group entity, has disclosed the sale of 67,000 equity shares in Vivo Bio Tech Limited on June 23, 2026. This transaction represents 0.30% of the total shares and 0.22% of the diluted share capital before the sale. Following the sale, Shri Shri Resorts Private Limited holds no shares in Vivo Bio Tech Limited. The sale was conducted via open market transaction. The total diluted share capital of Vivo Bio Tech Limited after the transaction is based on the assumption of conversion of pending warrants and exercise of outstanding ESOPs.

Shri Shri Resorts Private Limited, a promoter group entity, has sold 10,00,000 equity shares of Vivo Bio Tech Limited on June 8, 2026. This sale represents 4.51% of the total share capital. Following the transaction, Shri Shri Resorts' holding in Vivo Bio Tech has reduced to 67,000 shares, or 0.30% of the total share capital. The sale was conducted via an on-market transaction. The total diluted share capital of Vivo Bio Tech is noted as 2,99,50,520 equity shares.

Vivo Bio Tech Ltd, through its Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, has reported on the re-lodgement of transfer requests for physical shares for the period ended May 2026. As per SEBI circular dated January 30, 2026, the company confirmed that no requests were processed and no requests were received during the month of May 2026 under the special window provided by SEBI. This update is for information and records.

Vivo Bio Tech Ltd's board approved the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. They also approved the re-appointment of Mr. Kalyan Ram Mangipudi as a Whole-time Director for 5 years, subject to shareholder approval. Additionally, the board approved material related party transactions, also subject to shareholder approval via postal ballot, and the appointment of a consultant/advisor for a proposed Scheme of Arrangement/Amalgamation.

Vivo Bio Tech Ltd's board approved the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. They also approved the re-appointment of Mr. Kalyan Ram Mangipudi as a Whole-time Director for 5 years, subject to shareholder approval. Additionally, the board approved material related party transactions, also subject to shareholder approval via postal ballot, and the appointment of a consultant/advisor for a proposed Scheme of Arrangement/Amalgamation.

Vivo Bio Tech Ltd's board approved the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026. The board also approved the re-appointment of Mr. Kalyan Ram Mangipudi as a Whole-time Director for 5 years, subject to shareholder approval. Additionally, the board considered and approved material related party transactions, also subject to shareholder approval via postal ballot, and approved the appointment of a consultant/advisor for a proposed Scheme of Arrangement/Amalgamation.

Vivo Bio Tech Ltd has rescheduled its Board of Directors meeting to May 30, 2026, to consider and approve the audited standalone & consolidated financial results for the fourth quarter and year ended March 31, 2026. The board will also consider the amalgamation of M/s. Shri Shri Resorts Private Limited with Vivo Bio Tech Limited. The trading window will remain closed until June 01, 2026.